Moreover, it has been reported that the therapeutic activity of IFN-β, an extensively used therapy in RRMS patients, depends on IFN-γ signaling because IFN-β treatment has no effect on the development of disease in IFN-γR-deficient mice [41]. Here, IFNB1 is linked to relapsing-remitting multiple sclerosis.